Nexalin Technologies Inc 뉴스 - NXL | 주식 나스닥

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

Source: GlobeNewswire Inc.

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced results from a clinical trial demonstrating improvements in memory and cognitive function for patients with mild Alzheimer’s disease using its proprietary Deep Intracranial Frequency Stimulation (DIFS) technology. The full results have been published in Alzheimer’s Research & Therapy, one of the leading peer-reviewed journals in the field, further underscoring the scientific rigor and clinical importance of this research. The study can be accessed here.
The study, which enrolled 46 patients, showed that those in the DIFS group (23 patients) saw notable improvements in key cognitive markers, including significant gains in Mini-Mental State Examination (MMSE) scores (p = 0.041) and Montreal Cognitive Assessment (MoCA) scores (p = 0.025). The intervention also led to increased local neural activity in the hippocampus, a crucial area of the brain for memory processing, as revealed by functional MRI (fMRI) scans. Notably, the fMRI results showed that Nexalin’s DIFS treatment increased blood flow to the hippocampal regions, areas critical to memory function, further emphasizing the potential of this non-invasive therapy in combating neural decline associated with Alzheimer’s disease.

Key Findings:

Significant Memory Function Improvement: The DIFS group exhibited a statistically significant improvement in memory, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), compared to the sham group.
Cognitive Gains: Patients treated with DIFS saw meaningful progress in global cognitive function, with significant increases in Mini-Mental State Examination (MMSE) scores (p = 0.041) and Montreal Cognitive Assessment (MoCA) scores (p = 0.025).
Increased Hippocampal Activity and Blood Flow: Functional MRI (fMRI) revealed enhanced neural activity and increased blood flow in the hippocampus, a critical region for memory processing, suggesting that DIFS may positively influence brain function and slow the progression of Alzheimer’s disease.
Tolerability: The treatment was well-tolerated, with minor side effects such as mild tingling during stimulation sessions, all of which resolved quickly.
Dr. David Owens, Chief Medical Officer of Nexalin, commented, “We are thrilled with the results from the TRANSFORM-AD study, particularly the significant improvement in memory function. This study marks a major milestone for Nexalin’s Deep Intracranial Frequency Stimulation technology and validates our belief that non-invasive brain stimulation has the potential to transform the treatment landscape for Alzheimer’s disease. Improving cognitive outcomes, especially in memory, is crucial for enhancing the quality of life for patients and their families. The fMRI data showing increased blood flow to the hippocampal regions further emphasizes the potential of this therapy in addressing the underlying neural decline seen in Alzheimer’s patients. These findings are especially encouraging given the limited treatment options currently available for Alzheimer’s disease, which focus largely on managing symptoms rather than addressing the underlying neural decline.”

Mark White, CEO of Nexalin Technology, further noted, “Our DIFS technology shows great promise as a drug-free alternative or in combination with existing treatments by working directly on the brain's electrical activity to modulate cognition. The increase in both neural activity and blood flow in critical areas like the hippocampus indicates that this therapy could potentially slow disease progression. Looking ahead, we have already started planning a robust clinical trial utilizing different waveform frequencies to enhance the clinical response. We remain committed to advancing our patented technology and are actively exploring potential partnerships with the aim of offering a safe, effective, and non-invasive option for patients worldwide suffering from Alzheimer’s and other devastating mental health conditions.”

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Nexalin Technologies Inc (NXL)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

NXL 뉴스

New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nexalin Technology CEO Provides Letter to Shareholders

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Form 8-K - Current report

Veritone and Nuix Combine AI Expertise to Offer Turn-Key Solutions for Growing Volumes of Video and Audio Data

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

NXL Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Nexalin Technologies Inc (NXL) 뉴스

Nexalin Technologies Inc (NXL)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

NXL 뉴스

New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nexalin Technology CEO Provides Letter to Shareholders

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Form 8-K - Current report

Veritone and Nuix Combine AI Expertise to Offer Turn-Key Solutions for Growing Volumes of Video and Audio Data

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

NXL Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기